ANTI-GROWTH HORMONES
For Treatment of Growth Hormone Excess, Acromegaly, and Related Disorders
WHO-GMP Compliant | Human Use | Hormonal Therapy Portfolio
🧠 Overview
Anti-growth hormones are prescribed for conditions involving excessive growth hormone (GH) production, such as:
-
Acromegaly
-
Gigantism
-
Pituitary Adenomas
-
Neuroendocrine Tumors (NETs)
-
Cushing’s Disease (in some cases)
They help normalize GH/IGF-1 levels, control tumor growth, and improve clinical symptoms.
💊 PRODUCT CATALOG
| Brand Name | Generic Name | Strength | Form | Primary Use |
|---|---|---|---|---|
| Sandostatin | Octreotide Acetate | 0.05 mg/mL, 0.1 mg/mL | Injection (Ampoule / Vial) | Acromegaly, carcinoid tumors |
| Sandostatin LAR | Octreotide Acetate (Depot) | 10 mg, 20 mg, 30 mg | Long-Acting Injection | Monthly treatment of acromegaly |
| Somatuline Depot | Lanreotide Acetate | 60 mg, 90 mg, 120 mg | Prefilled Syringe | Acromegaly, NETs |
| Signifor | Pasireotide | 0.3 mg/mL – 0.9 mg/mL | Injection (SC) | Cushing’s disease, acromegaly |
| Pegvisomant (Somavert) | Pegvisomant | 10 mg, 15 mg, 20 mg | Injection (Powder for solution) | GH receptor antagonist, acromegaly |
Mechanism of Action
-
Somatostatin Analogs (Octreotide, Lanreotide, Pasireotide): Inhibit GH release from the pituitary gland.
-
GH Receptor Antagonist (Pegvisomant): Blocks GH action at the target tissue level.
📦 Packaging & Export Details
-
Cold-chain compliant (2–8°C)
-
WHO-GMP certified plants
-
Available with multilingual labeling
-
Customizable export packaging
-
Supplied with COA, COPP, Stability Data
📑 Dossier & Documentation Available:
-
CTD Dossier (Modules 1–5)
-
Certificate of Pharmaceutical Product (COPP)
-
Free Sale Certificate
-
GMP, FSC, and COA
-
Bioequivalence data (for certain molecules)
🌍 Target Markets:
-
Oncology & Endocrinology centers
-
Hormone therapy clinics
-
Government tenders and hospital supply
-
Regulated and semi-regulated markets